Impact of sample size on variation of adverse events and preventable adverse events: systematic review on epidemiology and contributing factors by Lessing, Constanze et al.
Impact of sample size on variation of adverse events
and preventable adverse events: systematic review
on epidemiology and contributing factors
Constanze Lessing,
1 Astrid Schmitz,
1 Bernhard Albers,
2 Matthias Schrappe
1
ABSTRACT
Objectives To perform a systematic review of the
frequency of (preventable) adverse events (AE/PAE) and
to analyse contributing factors, such as sample size,
settings, type of events, terminology, methods of
collecting data and characteristics of study populations.
Review methods Search of Medline and Embase from
1995 to 2007. Included were original papers with data
on the frequency of AE or PAE, explicit deﬁnition of study
population and information about methods of
assessment. Results were included with percentages of
patients having one or more AE/PAE. Extracted data
enclosed contributing factors. Data were abstracted and
analysed by two researchers independently.
Results 156 studies in 152 publications met our
inclusion criteria. 144/156 studies reported AE, 55 PAE
(43 both). Sample sizes ranged from 60 to 8493876
patients (median: 1361 patients). The reported results
for AE varied from 0.1% to 65.4%, and for PAE from 0.1%
to 33.9%. Variation clearly decreased with increasing
sample size. Estimates did not differ according to setting,
type of event or terminology. In studies with fewer than
1000 patients, chart review prevailed, whereas surveys
with more than 100000 patients were based mainly on
administrative data. No effect of patient characteristics
was found.
Conclusions The funnel-shaped distribution of AE and
PAE rates with sample size is a probable consequence of
variation and can be taken as an indirect indicator of
study validity. A contributing factor may be the method
of data assessment. Further research is needed to
explain the results when analysing data by types of event
or terminology.
INTRODUCTION
Following the Institute of Medicine (IOM) report
‘To Err is Human’ in 1999, there has been much
debate on the true incidence of adverse events (AE),
and preventable adverse events (PAE).
1 Several
studies at national level and with the Harvard
Medical Practice Design (see below) have found
results for AE up to 16.6%, and for PAE up to
8.4%
2e12 of inpatients. Variations in the ﬁgures
were soon considered, and several systematic
reviews have covered this issue.
13
Systematic reviews are restricted by the diversity
of studies. One strategy to deal with it is to reﬁne
research so as to focus on particular healthcare
settings or subgroups of endpoints such as medi-
cation-related events
14e18 or events leading to
hospital admission.
19e24 Only loose attempts have
been made in mapping AE across the total health-
care system comprehensively, however.
25e27
The present systematic review aims to specify
the overall incidence of AE and PAE across all
settings and procedures, so as to describe the
inﬂuence of heterogeneity factors such as sample
size, settings, type of events, terminology, methods
of collecting data or characteristics of the study
population. We hypothesise that variation of inci-
dence is explained primarily by sample size.
METHODS
Search strategy
The present article is part of a broader literature
research on the epidemiology of patient safety,
28
and looks at papers giving frequencies of AE and
PAE as percentages of patients affected. We began
with a search in Medline and Embase for studies
published between January 1995 and October 2007.
Key words (truncated) were: ‘AE*,’‘ PAE*,’‘ negli-
gent AE*,’‘ adverse medical device event*,’‘ medi-
cation error*,’‘ medical error*,’‘ near miss*,’
‘adverse drug event*’ and ‘iatrogenic illness*.’ This
search was limited to titles and abstracts. Refer-
ences cited in the studies retrieved were examined
in order to identify additional publications.
Articles in English, German, Spanish, French,
Portuguese, Danish and Norwegian were consid-
ered. Other languages were approved when there
was an English abstract containing data essential
for extraction. Articles identiﬁed were reviewed at
full-text level.
Selection
To be included, studies had to meet the following
ﬁve criteria: (1) original paper; (2) a speciﬁed study
population; (3) data collected on AE or PAE or both;
(4) explicit information given about the study
method; and (5) results reported as percentages of
patients affected. AE was deﬁned as any patient-
related injury caused by clinical management rather
than by the underlying disease, and PAE was
deﬁned as an AE resulting from error, and therefore
avoidable.
1 22 9Patient populations might represent
all patients in an institution, patients related to
ad e ﬁned medical specialty, or patients in an entire
sector of care such as drug therapy or nosocomial
infections.
A study was considered as an article on a single
study population. Papers reporting results from
different study populations were regarded as two or
more studies. In the case of duplicate publications,
only the primary or the one reporting overall results
was included. Intervention studies were included
with baseline data before the implementation of
risk prevention. When several assessment methods
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Original researchwere used, we extracted combined results as far as possible.
Studies limited to single diseases or isolated procedures were
excluded.
Data abstraction
Retrieved studies were assessed independently by two reviewers
and controlled twice. Discrepancies were resolved by discussion.
Data on the frequency of AE and PAE were extracted. Additional
variables were the number of patients included, information on
healthcare settings, classiﬁcation according to types of event and
terminology, method of collecting data and patient characteris-
tics. We distinguished between medication-related, procedure-
related and all types of events. We also distinguished between
AE terminologies used by different authors. Two main groups
were discerned. The ﬁrst group refers to the deﬁnition of the
IOM, ‘an AE is an injury resulting from a medical intervention,
or in other words, it is not due to the underlying disease’.
1 The
second group apply to the deﬁnition due to the WHO of adverse
drug events/adverse drug reactions as ‘any response to a drug
which is noxious, unintended and which occurs at doses
normally used in man for the prophylaxis, diagnosis or therapy
of disease’.
30 All other deﬁnitions were summarised in a third
deﬁnition group. Among methods of collecting data, we distin-
guished between chart review, computer-based alerts, direct
observation, voluntary reporting, critical incident reporting
systems, interviews, clinical surveillance and the analysis of
administrative data, usually in the form of codes from the
International Statistical Classiﬁcation of Diseases and Related
Health Problems (ICD).
31 We chose to distinguish between three
types of chart review: prospective, retrospective and the Harvard
Medical Design. The latter was developed especially to detect AE
and PAE, and consists of a retrospective structured two-staged
review process.
32 33
Quantitative data synthesis
Abstracted data were entered into a Microsoft Access database
for further analysis (Microsoft, Seattle, Washington). Frequen-
cies of outcome measures were recorded or calculated as
numbers and percentages of patients. Data were rounded to one
decimal place. Patient subgroups were totalled, if we were sure
that every patient was included only once.
RESULTS
Trial ﬂow
Our primary research found a total of 241 studies in 230
publications that matched our inclusion criteria. A total of 156
studies gave results as percentages of patients affected by AE or
PAE, see ﬁgure 1 (full list of references in Appendix 1, available
online only).
Study characteristics
In total, the 156 studies in our review reported results on
23696252 patients. Sample size varied from 60 patients
34 to
8493876 patients.
35 The median sample size was 1361 patients,
the 25th percentile was 379 patients, and the 75th percentile
was 14766 patients.
AE as a single outcome measure was observed in 101/156
(64.7%) of studies, 12 (7.8%) observed PAE, and 43 (27.6%)
observed both. Studies were performed in 27 countries, primarily
in highly developed industrial countries, headed by the USA (51
surveys). Most studies were short-term; 55.1% lasted more than
6 months, but only 25.6% lasted more than 1 year. Patients were
treated in distinct healthcare settings. One hundred and one
studies examined inhospital patients, nine surveys looked at
ambulatory care, 39 looked at ambulant patients leading to
hospital admission, three studies took place in long-term care,
and four studies were conducted in other settings. When
samples consisted of hospital patients, tertiary hospitals and
academic centres prevailed. Most studies were limited to single
institutions (101/156 cases). In general, all medical disciplines
were concerned (17 medical specialties were distinguished), but
when a speciﬁc choice was made, this depended principally on
the organisational structure of the wards and hospital. Ninety-
seven of 156 surveys concentrated on a single discipline. Thirty-
nine of these were concerned with internal medicine, 16 with
paediatrics and nine with surgery. We also found that 50/156
studies reported on all types of events, 99/156 were medication-
related, and 7/156 were procedure-related.
Studies used different methods for collecting data. Ninety-
seven surveys were restricted to a single collection method, and
59 papers used a combination of two or more methods. As
a single measuring instrument, a chart review prevailed in 43/97
studies, followed by clinical surveillance (13/97) and ICD codes
(11/97). Among combinations, the use of chart review with
interviews was most common (19/59). A summary of all studies
included is given in Appendix 2, available online only.
Incidence of AE and PAE by sample size
Frequencies of AE ranged from 0.1% to 65.4%. Most studies
(129/156) reported results between 0.1% and 30% (median 8.9%,
IQR 12.9). Incidences of PAE ranged from 0.1% to 33.9%. Almost
all studies (53/55) reported results between 0.1% and 20%
(median 4.8%, IQR 5.4).
To provide a more detailed picture of the distribution of
results, we plotted the results against study size. Figure 2 shows
the distribution of AE estimates in correlation to the size of the
study population.
We observe a broad variation in smaller studies having fewer
than 1000 patients. In studies with more than 1000 patients, the
spread decreases rapidly, and even falls below 20% in studies
with more than about 2000 patients. With only one exception,
the results of surveys with approximately 15000 patients or
more do not exceed 10%.
36
For PAE, the plot looks similar, although extreme outliers are
missing within small studies (ﬁgure 3); however, the fraction of
Publications for search terms
In Medline and Embase:
n = 44842 publications
Excluded, not meeting study
criteria:
n = 44677 publications
Retrieved for study criteria:
n = 165 publications
n = 156 studies
Publications reporting AE%
PAE% included in review:
n = 152 publications
Publications included in original
search:
n = 230 publications
Excluded, not reporting AE% or
PAE%
n = 78 publications
Retrieved from reference
lists:
n = 65 publications
Figure 1 Flow chart of studies retrieved and included in the systematic
review. AE, adverse event; PAE, preventable adverse event.
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Original researchsmall studies is smaller for PAE than for AE, and the same is true
for very large studies.
Nonetheless, percentages clearly decrease with sample size. In
studies with approximately 2000 patients, the results fall below
10%, and below the 1% mark in studies with more than 20000
patients. All scatter plots exhibit a visible correlation between
the frequency of AE and PAE and sample size.
Effect of setting, types of events, terminology and methods of
collecting data
We next analysed whether variation is due to further factors. We
found that results do not differ between healthcare settings,
countries or medical specialties. More surprisingly, we did not
even ﬁnd any clear disparities between different types of events,
although the frequency of AE related to medications or proce-
dures is expected to be lower than the overall results. Figure 4
shows the distribution for adverse drug events, procedure-related
events and all types of AE (ﬁgure 4).
The data for terminology show a similar distribution. There is
no difference in variation between studies using the terminology
of the IOM, the WHO or others (ﬁgure 5, a list of all deﬁnitions
of AE used is given in Appendix 3, available online only).
In relation to data-collecting methods, there is no difference in
estimates between studies that use a single method to detect
events, and surveys that operate with two or more methods. In
contrast assessment techniques differ according to sample size,
especially for AE (ﬁgure 6).
Interviews as a single method are restricted to small studies
with some hundred patients included,
37e42 whereas compila-
tions of ICD codes are used in large trials involving up to
millions of patients.
43e51 Six of nine surveys with more than
100000 patients are based on ICD codes, and the frequencies of
AE in these studies range from 0.1% to 8.3%. All studies with
results exceeding 30% and one single method to detect AE rely
on prospective or retrospective chart review. Also, 8/9 surveys
with combined methods use prospective chart review, mainly in
combination with interviews (3/8). The distribution is less clear
for PAE.
Characteristics of study populations
Information on the effect of patient characteristics was incon-
sistent. The distribution of gender is displayed in 46/156
surveys; 58/156 studies give the mean ages. Only 54/156 studies
report health status, referring mainly to the Charlson Index (11/
54).
52 Eighty-one of 156 surveys report on patient deaths. None
of these data sufﬁce to give information about possible depen-
dence of variation on study population characteristics.
DISCUSSION
Inoursystematicreview,weincluded156studiesonthefrequency
of AE and PAE. Studies were of great heterogeneity, and estimates
varied widely from 0.1% to 65.4% for AE, and from 0.1% to 33.9%
for PAE. Previous reviews found less variation. Von Laue et al
compiled estimates for AE ranging between 2.9% and 16.6%,
Aranaz et al from 3.7% to 16.6%, and de Vries et al from 4.6% to
12.4%. Discrepancies are largely because search strategies were
more contracted, and the number of studies included was smaller.
Figure 2 Adverse event estimates in correlation to sample size
(n¼144 studies), sample size displayed with half logarithmic-scale.
Figure 3 Preventable adverse event estimates in correlation to sample
size (n¼55 studies), sample size displayed with half logarithmic-scale.
Figure 4 Adverse event estimates by event type (n¼144 studies).
Figure 5 Adverse event estimates by AE terminology (n¼144 studies).
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Original researchOur aim was to display the overall body of published evidence
in order to shed light on the diversity of studies and results. To
consider study size as an approximation for strength of evidence,
we plotted outcomes against the size of the study population
and observed that variation decreased with the number of
patients included. As one would expect results to spread in small
studies as a simple rule of statistics, we interpret the distribution
of results as an indirect indicator for validity. This pattern was
much clearer for AE than for PAE, due primarily we believe to
the smaller number of studies on PAE. This consequence of
missing data has been described in the context of meta-
analyses.
53
We found no other factors to explain this pattern of variation.
Neither different settings nor event types had any effect, that is,
we found no differences between frequencies reported by
surveys on the total of events and surveys examining medica-
tion-related or procedure-related AE only. The same is true for
terminology; diverse deﬁnitions of AE make no difference to
frequencies. One reason might be indifference to precise deﬁni-
tion of terms. For example, few papers using the WHO termi-
nology differentiate between adverse drug reactions and adverse
drug events, terms sometimes used to distinguish between
preventable and non-preventable patient injuries. These ﬁndings
suggest that research methods should be reﬁned, and results may
not always display the true dimension of AE and PAE.
Very large surveys show a clear tendency for results to be less
than 1%. This could be due to the relation between sample size
and assessment methods. Whereas large surveys with more than
100000 patients are almost exclusively restricted to ICD-coded
events, many small trials prefer chart review, or combinations
with chart review. ICD coding is able to display only a fraction
of events, which might explain the comparatively low
estimates.
54e56 Conversely, this does not follow for small studies
with chart review. The assumption that high frequencies may
correlate with small studies because they look at cases more
carefully is opposed by the observation that results are not
restricted to remarkably high results but show a distribution
which is primarily due to statistical dispersion, and only addi-
tionally fortiﬁed by the choice of methods to collect data.
Another observation is that papers with above-average results
indicate that the majority involved high-risk patients and very
old or very young patients. Eight of 16 publications with results
on AE above 30% dealt with elderly patients,
57e64 and two
observed children.
65 66 Unfortunately, data were not sufﬁcient
for further analysis.
We conclude that the precision of AE and PAE estimates
depends primarily on sample size and to some degree on
methods to collect data. This second observation remains difﬁ-
cult for interpretation. In our judgement as a consequence the
informative value of very small surveys should be considered
with scepticism, as well as that of very large ones. Since 54.9%
of studies on AE (84/153) and 60.3% of studies on PAE (35/58)
deal with study populations either smaller than 1000 patients or
larger than 50000 patients the generalisibility of these papers
must be reassessed.
We believe the present review to be the largest systematic
review of the incidence of AE and PAE.
18 24 Only one previous
review detected a correlation between incidence and sample size
but did not give any explanation.
24 Others suggested explana-
tions but did not verify these.
20 22 24
The present review has limitations. It is part of a wider
research effort and is limited to surveys of the percentages of
AE/PAE. Consequently, estimates of errors or near misses were
not considered. Another limiting factor is that PAE has not yet
been investigated to the same extent as AE. Also, we searched
only the Medline and Embase databases. Due to our broad
research strategy, results exhibit a high heterogeneity, so there
was no indication to summarise results in a meta-analysis.
Our ﬁndings afﬁrm that AE and PAE are serious problems
across all healthcare settings and medical procedures, but some
questions remain about the consistency of methods of collecting
and reporting data. Further research should concentrate on
advancing methods especially for small settings and speciﬁc
types of event.
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